VRCA · Insider Trading
Verrica Pharmaceuticals Inc. Common Stock
Every open-market purchase and sale reported by VRCA officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-18 | Jayson Rieger | CEO and President | Buy | +25,000 | +$125.75K |
| 2026-08-18 | David Zawitz | Chief Operating Officer | Buy | +6,000 | +$29.88K |
| 2026-08-18 | John J. Kirby | Interim CFO | Buy | +5,000 | +$24.65K |
| 2026-08-18 | Noah L. Rosenberg | CMO | Buy | +6,230 | +$30.61K |
| 2026-06-09 | Jayson Rieger | CEO and President | A | +512,269 deriv. | — |
| 2026-06-09 | Noah L. Rosenberg | CMO | A | +233,840 deriv. | — |
| 2026-06-09 | David Zawitz | Chief Operating Officer | A | +171,340 deriv. | — |
| 2026-06-09 | Lawrence Eichenfield | Director | A | +16,000 deriv. | — |
| 2026-06-09 | Diem Nguyen | Director | A | +16,000 deriv. | — |
| 2026-06-09 | Mark A Prygocki Sr | Director | A | +16,000 deriv. | — |
| 2026-06-09 | Gavin Corcoran | Director | A | +16,000 deriv. | — |
| 2025-12-30 | John J. Kirby | Interim CFO | A | +10,000 | — |
| 2025-11-25 | Noah L. Rosenberg | CMO | Buy | +2,357 | +$10.00K |
| 2025-11-25 | John J. Kirby | Interim CFO | Buy | +3,536 | +$15.00K |
| 2025-11-25 | David Zawitz | Chief Operating Officer | Buy | +10,000 | +$42.42K |
| 2025-11-25 | Paul B Manning | Director | Buy | +4,126,142 | +$17.51M |
| 2025-11-25 | Jayson Rieger | CEO and President | Buy | +94,311 | +$400.11K |
| 2025-06-09 | Gavin Corcoran | Director | A | +20,000 deriv. | — |
| 2025-06-09 | Mark A Prygocki Sr | Director | A | +20,000 deriv. | — |
| 2025-06-09 | Lawrence Eichenfield | Director | A | +20,000 deriv. | — |
| 2025-06-09 | Diem Nguyen | Director | A | +20,000 deriv. | — |
| 2025-04-02 | Gavin Corcoran | Director | A | +17,502 deriv. | — |
| 2025-03-26 | Noah L. Rosenberg | CMO | A | +325,000 deriv. | — |
| 2025-03-18 | Jayson Rieger | CEO and President | A | +850,000 deriv. | — |
| 2025-03-18 | Christopher G. Hayes | CHIEF LEGAL OFFICER | Sell | −4,315 | −$2.80K |
| 2025-02-06 | Gary Goldenberg | Chief Medical Officer | A | +50,000 | — |
| 2025-02-06 | Christopher G. Hayes | CHIEF LEGAL OFFICER | A | +150,000 | — |
| 2025-02-06 | Ted White | PRESIDENT AND CEO | A | +150,000 | — |
| 2025-02-06 | Joe Bonaccorso | CHIEF COMMERCIAL OFFICER | A | +125,000 | — |
| 2025-02-06 | Terry Kohler | CHIEF FINANCIAL OFFICER | A | +125,000 | — |
| 2024-12-09 | David Zawitz | Chief Operating Officer | A | +950,000 deriv. | — |
| 2024-11-26 | Jayson Rieger | CEO and President | MIXED | +330,898 | — |
| 2024-11-26 | John A Stalfort III | Director | MIXED | +1,173,595 | — |
| 2024-11-26 | Paul B Manning | Director | MIXED | +22,471,348 | — |
| 2024-11-06 | Jayson Rieger | CEO and President | A | +2,000,000 deriv. | — |
| 2024-11-06 | John J. Kirby | Interim CFO | A | +54,267 | — |
| 2024-10-11 | Christopher G. Hayes | CHIEF LEGAL OFFICER | A | +50,000 deriv. | — |
| 2024-09-23 | Paul B Manning | Director | G | −891,870 | — |
| 2024-08-28 | Joe Bonaccorso | CHIEF COMMERCIAL OFFICER | Sell | −33,702 | −$87.85K |
| 2024-08-28 | Ted White | PRESIDENT AND CEO | Sell | −34,000 | −$88.64K |
| 2024-08-28 | Christopher G. Hayes | CHIEF LEGAL OFFICER | Sell | −35,713 | −$93.09K |
| 2024-08-28 | Gary Goldenberg | Chief Medical Officer | Sell | −13,489 | −$35.16K |
| 2024-08-28 | Terry Kohler | CHIEF FINANCIAL OFFICER | Sell | −29,719 | −$77.47K |
| 2024-07-23 | Ted White | PRESIDENT AND CEO | Sell | −32,623 | −$230.31K |
| 2024-07-23 | Joe Bonaccorso | CHIEF COMMERCIAL OFFICER | Sell | −25,576 | −$180.56K |
| 2024-07-23 | Gary Goldenberg | Chief Medical Officer | Sell | −18,507 | −$130.65K |
| 2024-07-23 | Christopher G. Hayes | CHIEF LEGAL OFFICER | Sell | −21,740 | −$153.48K |
| 2024-06-07 | Craig Ballaron | Director | A | +20,000 deriv. | — |
| 2024-06-07 | Lawrence Eichenfield | Director | A | +20,000 deriv. | — |
| 2024-06-07 | Diem Nguyen | Director | A | +20,000 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Paul B Manning | Director | 7,306,561 | $26.23M |
| Jayson Rieger | CEO and President | 202,823 | $728.13K |
| John A Stalfort III | Director | 187,380 | $672.69K |
| Ted White | PRESIDENT AND CEO | 27,879 | $100.09K |
| David Zawitz | Chief Operating Officer | 27,000 | $96.93K |
| John J. Kirby | Interim CFO | 23,962 | $86.02K |
| Joe Bonaccorso | CHIEF COMMERCIAL OFFICER | 18,774 | $67.40K |
| Christopher G. Hayes | CHIEF LEGAL OFFICER | 17,646 | $63.35K |
| Terry Kohler | CHIEF FINANCIAL OFFICER | 12,500 | $44.88K |
| Gary Goldenberg | Chief Medical Officer | 12,011 | $43.12K |
| Noah L. Rosenberg | CMO | 6,557 | $23.54K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the VRCA quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.